Leptin, resistin and visfatin: The missing link between endocrine metabolic disorders and immunity

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Al Suhaimi, Ebtesam A ^a   Shehzad, Adeeb ^b  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b Kyungpook National University   (South Korea)

Author keywords

Adipocytokines; Diabetes; Endocrine; Immunity; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCOSE TRANSPORTER 4; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN C FOS; PROTEIN KINASE B; RECOMBINANT LEPTIN; RECOMBINANT PROTEIN; RECOMBINANT RESISTIN; RECOMBINANT VISFATIN; RESISTIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HORMONE;

ADIPOCYTE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BODY MASS; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENDOCRINE DISEASE; ENDOCRINE METABOLIC DISEASE; ENDOCRINE SYSTEM; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE ACTIVATION; METABOLIC DISORDER; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ENERGY METABOLISM; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ENDOCRINE SYSTEM DISEASES; ENERGY METABOLISM; HORMONES; HUMANS; IMMUNITY; INFLAMMATION; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

EID: 84876799918     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-12     Document Type: Review

References (153)

1. Development of brown and white adipose tissue. Hahn P, Novak M, J Lipid Res 1975 16 79 91 1168684
2. Adipose tissue as an endocrine organ. Kershaw EE, Flier JS, J Clin Endocrinol Metab 2004 89 2548 2556 10.1210/jc.2004-0395 15181022 (Pubitemid 38766330)
3. The adipose tissue-a novel endocrine organ of interest to the nephrologist. Wiecek A, Kokot F, Chudek J, Adamczak M, Nephrol Dial Transplant 2002 17 191 195 11812861 (Pubitemid 34157125)
4. Adiponectin: a key player in obesity related disorders. Matsuzawa Y, Curr Pharm Des 2010 16 1896 1901 10.2174/138161210791208893 20370675
5. Metabolic effects of obesity: A review. Singla P, Bardoloi A, Parkash AA, World J Diabetes 2010 1 76 88 10.4239/wjd.v1.i3.76 21537431
6. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Genc H, Dogru T, Tapan S, Kara M, Ercin CN, Aslan F, Kantarcioglu M, Karslioglu Y, Sertoglu E, Erbil MK, Bagci S, Scand J Gastroenterol 2011 46 1355 1361 10.3109/00365521.2011.603163 21770819
7. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y, Biochem Biophys Res Commun 2011 408 339 343 10.1016/j.bbrc.2011.04. 039 21514279
8. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Gualillo O, Gonzalez-Juanatey JR, Lago F, Trends Cardiovasc Med 2007 17 275 283 10.1016/j.tcm.2007.09.005 18021938 (Pubitemid 350087698)
9. Adipose tissue as an endocrine organ. Galic S, Oakhill JS, Steinberg GR, Mol Cell Endocrinol 2010 316 129 139 10.1016/j.mce.2009.08.018 19723556
10. APPL1: role in adiponectin signaling and beyond. Deepa SS, Dong LQ, Am J Physiol Endocrinol Metab 2009 296 22 36 18854421
11. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Tilg H, Moschen AR, Nat Rev Immunol 2006 6 772 783 10.1038/nri1937 16998510 (Pubitemid 44453463)
12. Adipocytokines as mediators of metabolic role of adipose tissue. Pandzic Jaksic V, Acta Med Croatica 2010 64 253 262 21688608
13. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Tilg H, Moschen AR, Clin Sci (Lond) 2008 114 275 288 10.1042/CS20070196 (Pubitemid 351294003)
14. From observation to experimentation: leptin action in the mediobasal hypothalamus. Williams KW, Scott MM, Elmquist JK, Am J Clin Nutr 2009 89 985S 990S 10.3945/ajcn.2008.26788D 19176744
15. Leptin in humans: lessons from translational research. Bluher S, Mantzoros CS, Am J Clin Nutr 2009 89 991S 997S 10.3945/ajcn.2008.26788E 19176740
16. Leptin secretion from subcutaneous and visceral adipose tissue in women. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P, Diabetes 1998 47 913 917 10.2337/diabetes.47.6.913 9604868 (Pubitemid 28255665)
17. The stomach is a source of leptin. Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN, Moizo L, Lehy T, Guerre-Millo M, Le Marchand-Brustel Y, Lewin MJ, Nature 1998 394 790 793 10.1038/29547 9723619 (Pubitemid 28391644)
18. Leptin and gastro-intestinal malignancies. Howard JM, Pidgeon GP, Reynolds JV, Obes Rev 2010 11 863 874 10.1111/j.1467-789X.2010.00718.x 20149119
19. Role of leptin in the neuroendocrine response to fasting. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS, Nature 1996 382 250 252 10.1038/382250a0 8717038 (Pubitemid 26251358)
20. Clinical review 94: What's in a name? In search of leptin's physiologic role. Flier JS, J Clin Endocrinol Metab 1998 83 1407 1413 10.1210/jc.83.5.1407 9589630 (Pubitemid 28500994)
21. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Koerner A, Kratzsch J, Kiess W, Best Pract Res Clin Endocrinol Metab 2005 19 525 546 10.1016/j.beem.2005.07.008 16311215 (Pubitemid 41819217)
22. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. Konturek PC, Konturek JW, Czesnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ, J Physiol Pharmacol 2005 56 Suppl 6 5 25 16340035 (Pubitemid 43120939)
23. Leptin-induced signal transduction pathways. Hegyi K, Fulop K, Kovacs K, Toth S, Falus A, Cell Biol Int 2004 28 159 169 10.1016/j.cellbi.2003.12.003 14984741 (Pubitemid 38230226)
24. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Uotani S, Bjorbaek C, Tornoe J, Flier JS, Diabetes 1999 48 279 286 10.2337/diabetes.48.2. 279 10334302 (Pubitemid 29061099)
25. Mechanisms of leptin action and leptin resistance. Myers MG, Cowley MA, Munzberg H, Annu Rev Physiol 2008 70 537 556 10.1146/annurev.physiol.70.113006. 100707 17937601 (Pubitemid 351738191)
26. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M, Blood 1999 93 1668 1676 10029596 (Pubitemid 29102495)
27. Expression of leptin receptor in lung: leptin as a growth factor. Tsuchiya T, Shimizu H, Horie T, Mori M, Eur J Pharmacol 1999 365 273 279 10.1016/S0014-2999(98)00884-X 9988112 (Pubitemid 29070774)
28. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM, Int J Obes Relat Metab Disord 2002 26 577 580 10.1038/sj.ijo.0801947 12075587 (Pubitemid 34407273)
29. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S, BMC Cancer 2010 10 320 10.1186/1471-2407-10-320 20569445
30. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hébert CC, EMBO J 2000 19 4046 4055 10.1093/emboj/19.15.4046 10921885 (Pubitemid 30608543)
31. The hormone resistin links obesity to diabetes. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA, Nature 2001 409 307 312 10.1038/35053000 11201732 (Pubitemid 32151228)
32. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilai N, Scherer PE, Mol Endocrinol 2002 16 1920 1930 10.1210/me.2002-0048 12145345 (Pubitemid 34828098)
33. Identification of murine and human XCP1 genes as C/EBP-epsilon-dependent members of FIZZ/Resistin gene family. Chumakov AM, Kubota T, Walter S, Koeffler HP, Oncogene 2004 23 3414 3425 10.1038/sj.onc.1207126 15064728 (Pubitemid 38669831)
34. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA, Biochem Biophys Res Commun 2003 300 472 476 10.1016/S0006-291X(02)02841-3 12504108 (Pubitemid 38375833)
35. Identification of an alternative splicing transcript for the resistin gene and distribution of its mRNA in human tissue. Nohira T, Nagao K, Kameyama K, Nakai H, Fukumine N, Okabe K, Kitano S, Hisatomi H, Eur J Endocrinol 2004 151 151 154 10.1530/eje.0.1510151 15248836 (Pubitemid 39117378)
36. Resistin- and Obesity-associated metabolic diseases. Lazar MA, Horm Metab Res 2007 39 710 716 10.1055/s-2007-985897 17952831 (Pubitemid 350099817)
37. Role of resistin in obesity, insulin resistance and Type II diabetes. Kusminski CM, McTernan PG, Kumar S, Clin Sci (Lond) 2005 109 243 256 10.1042/CS20050078 (Pubitemid 41337128)
38. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I, Science 2005 307 426 430 10.1126/science.1097243 15604363 (Pubitemid 40139988)
39. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F, Eur J Immunol 2002 32 3225 3234 10.1002/1521- 4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L 12555668 (Pubitemid 35414880)
40. Adipokine leptin in obesity-related pathology of breast cancer. Ray A, J Biosci 2012 37 289 294 10.1007/s12038-012-9191-9 22581334
41. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP, Cell 1996 84 491 495 10.1016/S0092-8674(00)81294-5 8608603 (Pubitemid 26060722)
42. Localization of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57BL/6J mice. Malik KF, Young WS 3rd, Endocrinology 1996 137 1497 1500 10.1210/en.137.4.1497 8625929 (Pubitemid 26098619)
43. Positional cloning of the mouse obese gene and its human homologue. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM, Nature 1994 372 425 432 10.1038/372425a0 7984236 (Pubitemid 24365442)
44. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS, Nat Med 1995 1 1311 1314 10.1038/nm1295-1311 7489415
45. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Segal KR, Landt M, Klein S, Diabetes 1996 45 988 991 10.2337/diabetes.45.7.988 8666154 (Pubitemid 26225519)
46. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr, J Clin Invest 1997 99 385 390 10.1172/JCI119171 9022070 (Pubitemid 27414794)
47. Synchronous esophageal and renal cell carcinoma. Kobayashi S, Kabuto T, Doki Y, Yamada T, Miyashiro I, Murata K, Hiratsuka M, Kameyama M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S, Dis Esophagus 2000 13 305 310 10.1046/j.1442-2050.2000.00125.x 11284979 (Pubitemid 32396524)
48. The leptin receptor. Tartaglia LA, J Biol Chem 1997 272 6093 6096 9102398 (Pubitemid 27118072)
49. Leptin signaling in the central nervous system and the periphery. Bjorbaek C, Kahn BB, Recent Prog Horm Res 2004 59 305 331 10.1210/rp.59.1.305 14749508
50. The role of leptin in the regulation of energy balance. Sousa M, Bras-Silva C, Leite-Moreira A, Acta Med Port 2009 22 291 298 Portuguese 19686630
51. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, Cirillo T, Cafiero M, Natale S, Astarita C, Int J Cardiol 2009 134 414 416 10.1016/j.ijcard.2007.12.087 18378021
52. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, Wang Y, Banks AS, Lavery HJ, Haq AK, Maratos-Flier E, Neel BG, Schwartz MW, Myers MG Jr, Nature 2003 421 856 859 10.1038/nature01388 12594516 (Pubitemid 36254146)
53. Role of signal transducer and activator of transcription 3 in regulation of hypothalamic proopiomelanocortin gene expression by leptin. Munzberg H, Huo L, Nillni EA, Hollenberg AN, Bjorbaek C, Endocrinology 2003 144 2121 2131 10.1210/en.2002-221037 12697721 (Pubitemid 36543352)
54. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A, Nat Med 2004 10 739 743 10.1038/nm1071 15208705 (Pubitemid 38937640)
55. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Ueki K, Kondo T, Kahn CR, Mol Cell Biol 2004 24 5434 5446 10.1128/MCB.24.12.5434-5446.2004 15169905 (Pubitemid 38738176)
56. Neuronal suppressor of cytokine signaling-3 deficiency enhances hypothalamic leptin-dependent phosphatidylinositol 3-kinase signaling. Metlakunta AS, Sahu M, Yasukawa H, Dhillon SS, Belsham DD, Yoshimura A, Sahu A, Am J Physiol Regul Integr Comp Physiol 2011 300 1185 1193 10.1152/ajpregu.00794. 2010 21325649
57. Intracellular leptin-signaling pathways in hypothalamic neurons: the emerging role of phosphatidylinositol-3 kinase-phosphodiesterase-3B-cAMP pathway. Sahu A, Neuroendocrinology 2011 93 201 210 10.1159/000326785 21464566
58. The Src/PI3K/Akt pathway may play a key role in the production of IL-17 in obesity. Chen J, J Leukoc Biol 2010 87 355 author reply 357 10.1189/jlb.1009683 20194159
59. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B, J Biol Chem 2002 277 1794 1799 10.1074/jbc.M103728200 11707433 (Pubitemid 34968751)
60. Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Suganami E, Takagi H, Ohashi H, Suzuma K, Suzuma I, Oh H, Watanabe D, Ojima T, Suganami T, Fujio Y, Nakao K, Ogawa Y, Yoshimura N, Diabetes 2004 53 2443 2448 10.2337/diabetes.53.9.2443 15331557 (Pubitemid 39145601)
61. Adipose tissue angiogenesis. Hausman GJ, Richardson RL, J Anim Sci 2004 82 925 934 15032451 (Pubitemid 38572359)
62. Critical role of STAT3 in leptin's metabolic actions. Buettner C, Pocai A, Muse ED, Etgen AM, Myers MG Jr, Rossetti L, Cell Metab 2006 4 49 60 10.1016/j.cmet.2006.04.014 16814732 (Pubitemid 43942253)
63. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. Cohen SE, Kokkotou E, Biddinger SB, Kondo T, Gebhardt R, Kratzsch J, Mantzoros CS, Kahn CR, J Biol Chem 2007 282 23672 23678 10.1074/jbc.M704053200 17556363 (Pubitemid 47311938)
64. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Mojiminiyi OA, Abdella NA, Scand J Clin Lab Invest 2007 67 215 225 10.1080/00365510601032532 17366001 (Pubitemid 46410615)
65. Resistin expression in different adipose tissue depots during rat development. Oliver P, Pico C, Serra F, Palou A, Mol Cell Biochem 2003 252 397 400 10.1023/A:1025500605884 14577616 (Pubitemid 37220772)
66. Serum resistin (FIZZ3) protein is increased in obese humans. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV, J Clin Endocrinol Metab 2003 88 5452 5455 10.1210/jc.2002-021808 14602788 (Pubitemid 37452753)
67. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Ort T, Arjona AA, MacDougall JR, Nelson PJ, Rothenberg ME, Wu F, Eisen A, Halvorsen YD, Endocrinology 2005 146 2200 2209 10.1210/en.2004-1421 15705777 (Pubitemid 40577507)
68. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C, Cardiovasc Res 2006 70 146 157 10.1016/j.cardiores.2006.01.015 16515776
69. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. Solinas G, Karin M, FASEB J 2010 24 2596 2611 10.1096/fj.09-151340 20371626
70. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander? Ukkola O, Eur J Endocrinol 2002 147 571 574 10.1530/eje.0.1470571 12444887 (Pubitemid 35414553)
71. Resistine-a new hormone secreted by adipose tissue (adipose tissue in insulin resistance). Kochan Z, Karbowska J, Przegl Lek 2003 60 40 42 15106454
72. Resistin expression and regulation in mouse pituitary. Morash BA, Willkinson D, Ur E, Wilkinson M, FEBS Lett 2002 526 26 30 10.1016/S0014-5793(02) 03108-3 12208498 (Pubitemid 35245686)
73. Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Brunetti L, Orlando G, Recinella L, Michelotto B, Ferrante C, Vacca M, Eur J Pharmacol 2004 493 41 44 10.1016/j.ejphar.2004.04.020 15189762 (Pubitemid 38746930)
74. Central administration of resistin promotes short-term satiety in rats. Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A, Williams LM, Dickson SL, Dieguez C, Eur J Endocrinol 2005 153 1 5 10.1530/eje.1.01999 16131594 (Pubitemid 41410504)
75. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M, Diabetes 2005 54 2911 2916 10.2337/diabetes.54.10.2911 16186392 (Pubitemid 41401086)
76. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R, J Clin Endocrinol Metab 2006 91 3165 3170 10.1210/jc.2006-0361 16720654 (Pubitemid 44271773)
77. The adipokine visfatin is markedly elevated in obese children. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M, J Pediatr Gastroenterol Nutr 2006 43 548 549 10.1097/01.mpg.0000235749.50820.b3 17033537 (Pubitemid 44569022)
78. Serum concentration of visfatin in obese women. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M, Dabrowski P, Skorupa A, Metabolism 2007 56 1131 1134 10.1016/j.metabol.2007.04. 007 17618961 (Pubitemid 47021180)
79. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M, Diabetes Res Clin Pract 2008 79 412 418 10.1016/j.diabres.2007.09.019 18241953
80. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q, Cell Metab 2007 6 307 319 10.1016/j.cmet.2007.08.014 17908559 (Pubitemid 47468091)
81. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S, Cell Metab 2007 6 363 375 10.1016/j.cmet.2007.09.003 17983582 (Pubitemid 350011996)
82. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/ visfatin in rat obesity models. Mercader J, Granados N, Caimari A, Oliver P, Bonet ML, Palou A, Horm Metab Res 2008 40 467 472 10.1055/s-2008-1065324 18401839
83. Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Kloting N, Kloting I, Biochem Biophys Res Commun 2005 332 1070 1072 10.1016/j.bbrc.2005.05.058 15922301 (Pubitemid 40798194)
84. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Adya R, Tan BK, Punn A, Chen J, Randeva HS, Cardiovasc Res 2008 78 356 365 10.1093/cvr/cvm111 18093986 (Pubitemid 351556097)
85. Effects of leptin deficiency and short-term repletion on hepatic gene expression in genetically obese mice. Ferrante AW Jr, Thearle M, Liao T, Leibel RL, Diabetes 2001 50 2268 2278 10.2337/diabetes.50.10.2268 11574408 (Pubitemid 33641911)
86. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. Martin SS, Qasim A, Reilly MP, J Am Coll Cardiol 2008 52 1201 1210 10.1016/j.jacc.2008.05.060 18926322
87. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, Withers DJ, Gardiner JV, Bailey CJ, Bloom SR, J Clin Invest 1997 100 2729 2736 10.1172/JCI119818 9389736 (Pubitemid 28007540)
88. Obesity and the regulation of energy balance. Spiegelman BM, Flier JS, Cell 2001 104 531 543 10.1016/S0092-8674(01)00240-9 11239410 (Pubitemid 32201948)
89. The role of leptin in the regulation of carbohydrate metabolism. Tucholski K, Otto-Buczkowska E, Endokrynol Pol 2011 62 258 262 21717410
90. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. Morton GJ, J Physiol 2007 583 Pt 2 437 443 17584844 (Pubitemid 47343482)
91. Do leptin and insulin signal adiposity? Hillebrand JJ, Geary N, Forum Nutr 2010 63 111 122 19955779
92. Insulin, leptin and reward. Davis JF, Choi DL, Benoit SC, Trends Endocrinol Metab 2010 21 68 74 10.1016/j.tem.2009.08.004 19818643
93. Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice. Levi J, Huynh FK, Denroche HC, Neumann UH, Glavas MM, Covey SD, Kieffer TJ, Diabetologia 2012 55 752 762 10.1007/s00125-011-2426-8 22202803
94. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Schultze SM, Hemmings BA, Niessen M, Tschopp O, Expert Rev Mol Med 2012 14 1 22233681
95. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Kitamura T, Feng Y, Kitamura YI, Chua SC Jr, Xu AW, Barsh GS, Rossetti L, Accili D, Nat Med 2006 12 534 540 10.1038/nm1392 16604086
96. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC Jr, Roth RA, J Biol Chem 1998 273 11937 11943 10.1074/jbc.273.19.11937 9565622 (Pubitemid 28272103)
97. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. Kohn AD, Summers SA, Birnbaum MJ, Roth RA, J Biol Chem 1996 271 31372 31378 10.1074/jbc.271.49.31372 8940145 (Pubitemid 26408588)
98. The GLUT4 glucose transporter. Huang S, Czech MP, Cell Metab 2007 5 237 252 10.1016/j.cmet.2007.03.006 17403369 (Pubitemid 46477860)
99. GLUT4: a key player regulating glucose homeostasis? Insights from transgenic and knockout mice (review). Wallberg-Henriksson H, Zierath JR, Mol Membr Biol 2001 18 205 211 10.1080/09687680110072131 11681787 (Pubitemid 32971217)
100. The role of GLUT2 in dietary sugar handling. Leturque A, Brot-Laroche E, Le Gall M, Stolarczyk E, Tobin V, J Physiol Biochem 2005 61 529 537 10.1007/BF03168378 16669350
101. Functional properties and genomics of glucose transporters. Zhao FQ, Keating AF, Curr Genomics 2007 8 113 128 10.2174/138920207780368187 18660845 (Pubitemid 46690959)
102. Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism. Benomar Y, Naour N, Aubourg A, Bailleux V, Gertler A, Djiane J, Guerre-Millo M, Taouis M, Endocrinology 2006 147 2550 2556 10.1210/en.2005-1464 16497805
103. Leptin reduces the expression and increases the phosphorylation of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4 in muscle of ob/ob mice. Sainz N, Rodriguez A, Catalan V, Becerril S, Ramirez B, Lancha A, Burgos-Ramos E, Gomez-Ambrosi J, Fruhbeck G, PLoS One 2012 7 29389 10.1371/journal.pone. 0029389 22253718
104. Increased phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. Bruss MD, Arias EB, Lienhard GE, Cartee GD, Diabetes 2005 54 41 50 10.2337/diabetes.54.1.41 15616009 (Pubitemid 40105093)
105. Current views on type 2 diabetes. Lin Y, Sun Z, J Endocrinol 2010 204 1 11 10.1677/JOE-09-0260 19770178
106. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Martinez A, Castro A, Dorronsoro I, Alonso M, Med Res Rev 2002 22 373 384 10.1002/med.10011 12111750 (Pubitemid 34620473)
107. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. Clodfelder-Miller B, De Sarno P, Zmijewska AA, Song L, Jope RS, J Biol Chem 2005 280 39723 39731 10.1074/jbc.M508824200 16179343 (Pubitemid 41779105)
108. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR, Diabetes 2000 49 263 271 10.2337/diabetes.49.2.263 10868943 (Pubitemid 30071005)
109. Signal transduction: signaling specificity- a complex affair. Weston CR, Davis RJ, Science 2001 292 2439 2440 10.1126/science.1063279 11431552 (Pubitemid 32601644)
110. Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, Cowley MA, Cantley LC, Lowell BB, Elmquist JK, J Clin Invest 2008 118 1796 1805 10.1172/JCI32964 18382766 (Pubitemid 351632382)
111. Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Namkoong C, Kim MS, Jang PG, Han SM, Park HS, Koh EH, Lee WJ, Kim JY, Park IS, Park JY, Lee KU, Diabetes 2005 54 63 68 10.2337/diabetes.54.1.63 15616011 (Pubitemid 40105095)
112. Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Goren I, Muller E, Pfeilschifter J, Frank S, Am J Pathol 2006 168 765 777 10.2353/ajpath.2006. 050293 16507892 (Pubitemid 43327729)
113. Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Al-Harithy RN, Al-Ghamdi S, Ann Saudi Med 2005 25 283 287 16212119 (Pubitemid 41288663)
114. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS, J Clin Endocrinol Metab 2003 88 1730 1736 10.1210/jc.2002-021604 12679465 (Pubitemid 36623396)
115. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ, Eur J Endocrinol 2003 149 331 335 10.1530/eje.0.1490331 14514348 (Pubitemid 37304704)
116. Resistin gene expression in human adipocytes is not related to insulin resistance. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM, Obes Res 2002 10 1 5 10.1038/oby.2002.1 11786595 (Pubitemid 135686624)
117. Increased resistin gene and protein expression in human abdominal adipose tissue. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S, J Clin Endocrinol Metab 2002 87 2407 10.1210/jc.87.5.2407 11994397 (Pubitemid 34521539)
118. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G, Diabetes 2003 52 1611 1618 10.2337/diabetes.52.7.1611 12829623 (Pubitemid 36792447)
119. Resistin: a newly identified chemokine for human CD4-positive lymphocytes. Walcher D, Hess K, Berger R, Aleksic M, Heinz P, Bach H, Durst R, Hausauer A, Hombach V, Marx N, Cardiovasc Res 2010 85 167 174 10.1093/cvr/cvp278 19684036
120. Regulation of fasted blood glucose by resistin. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA, Science 2004 303 1195 1198 10.1126/science.1092341 14976316 (Pubitemid 38233585)
121. Activation of SOCS-3 by resistin. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA, Mol Cell Biol 2005 25 1569 1575 10.1128/MCB.25.4.1569- 1575.2005 15684405 (Pubitemid 40204931)
122. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. Shi H, Tzameli I, Bjorbaek C, Flier JS, J Biol Chem 2004 279 34733 34740 10.1074/jbc.M403886200 15181014 (Pubitemid 39318104)
123. Loss of resistin improves glucose homeostasis in leptin deficiency. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA, Ahima RS, Diabetes 2006 55 3083 3090 10.2337/db05-0615 17065346 (Pubitemid 44923646)
124. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Stofkova A, Endocr Regul 2010 44 25 36 10.4149/endo-2010-01-25 20151765
125. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Makimura H, Mizuno TM, Bergen H, Mobbs CV, Am J Physiol Endocrinol Metab 2002 283 1266 1271 12388167
126. Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. Bauer S, Neumeier M, Wanninger J, Walter R, Kopp A, Bala M, Schaffler A, Buechler C, J Diabetes Complications 2011 25 377 381 10.1016/j.jdiacomp.2011.06.001 21813294
127. Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. McGee KC, Harte AL, da Silva NF, Al-Daghri N, Creely SJ, Kusminski CM, Tripathi G, Levick PL, Khanolkar M, Evans M, Chittari MV, Patel V, Kumar S, McTernan PG, PLoS One 2011 6 20287 10.1371/journal.pone.0020287 21694775
128. Leptin and the immunosuppression of malnutrition. Grunfeld C, J Clin Endocrinol Metab 2002 87 3038 3039 10.1210/jc.87.7.3038 12107197 (Pubitemid 34816341)
129. Apoptotic pathways are inhibited by leptin receptor activation in neutrophils. Bruno A, Conus S, Schmid I, Simon HU, J Immunol 2005 174 8090 8096 15944317 (Pubitemid 40806320)
130. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gomez-Reino J, Gualillo O, Rheumatology (Oxford) 2006 45 944 950 10.1093/rheumatology/kel157 (Pubitemid 44283047)
131. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Stofkova A, Endocr Regul 2009 43 157 168 19908934
132. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C, Clin Exp Immunol 2003 133 11 19 10.1046/j.1365-2249.2003.02190.x 12823272 (Pubitemid 36791936)
133. Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats. Haas P, Straub RH, Bedoui S, Nave H, Regul Pept 2008 151 26 34 10.1016/j.regpep.2008.05.004 18556075
134. Leptin signaling protects NK cells from apoptosis during development in mouse bone marrow. Lo CK, Lam QL, Yang M, Ko KH, Sun L, Ma R, Wang S, Xu H, Tam S, Wu CY, Zheng BJ, Lu L, Cell Mol Immunol 2009 6 353 360 10.1038/cmi.2009.46 19887048
135. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Li Z, Lin H, Yang S, Diehl AM, Gastroenterology 2002 123 1304 1310 10.1053/gast.2002.35997 12360490
136. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Sennello JA, Fayad R, Morris AM, Eckel RH, Asilmaz E, Montez J, Friedman JM, Dinarello CA, Fantuzzi G, Endocrinology 2005 146 2157 2164 10.1210/en.2004-1572 15677756 (Pubitemid 40577500)
137. Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. Gruen ML, Hao M, Piston DW, Hasty AH, Am J Physiol Cell Physiol 2007 293 1481 1488 10.1152/ajpcell.00062.2007 17728393 (Pubitemid 350085627)
138. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? Napoleone E, Dis A, Amore C, Baccante G, di Febbo C, Porreca E, de Gaetano G, Donati MB, Lorenzet R, J Thromb Haemost 2007 5 1462 1468 10.1111/j.1538-7836. 2007.02578.x 17425664 (Pubitemid 46965376)
139. Preferential effects of leptin on CD4 T cells in central and peripheral immune system are critically linked to the expression of leptin receptor. Kim SY, Lim JH, Choi SW, Kim M, Kim ST, Kim MS, Cho YS, Chun E, Lee KY, Biochem Biophys Res Commun 2010 394 562 568 10.1016/j.bbrc.2010.03.019 20227394
140. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V, Cell Immunol 2000 199 15 24 10.1006/cimm.1999.1594 10675271 (Pubitemid 30118591)
141. Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI, J Leukoc Biol 2002 72 330 338 12149424
142. Adipose tissue lymphocytes: types and roles. Caspar-Bauguil S, Cousin B, Bour S, Casteilla L, Penicaud L, Carpene C, J Physiol Biochem 2009 65 423 436 10.1007/BF03185938 20358356
143. Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma. Leivo-Korpela S, Lehtimaki L, Vuolteenaho K, Nieminen R, Kankaanranta H, Saarelainen S, Moilanen E, J Inflamm (Lond) 2011 8 12 10.1186/1476-9255-8-12
144. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR, Biochem Biophys Res Commun 2003 309 286 290 10.1016/j.bbrc.2003.07. 003 12951047 (Pubitemid 37025889)
145. New role of resistin in lipopolysaccharide-induced liver damage in mice. Beier JI, Guo L, von Montfort C, Kaiser JP, Joshi-Barve S, Arteel GE, J Pharmacol Exp Ther 2008 325 801 808 10.1124/jpet.108.136721 18339969 (Pubitemid 351724330)
146. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T, Parhofer KG, Goke B, Broedl UC, Eur J Gastroenterol Hepatol 2007 19 1070 1074 10.1097/MEG.0b013e3282f16251 17998831 (Pubitemid 350125378)
147. Serum adiponectin and leptin concentrations in patients with chronic pancreatitis of alcoholic and nonalcoholic origin. Adrych K, Smoczynski M, Stelmanska E, Korczynska J, Goyke E, Swierczynski J, Pancreas 2008 36 120 124 10.1097/MPA.0b013e3181561187 18376301
148. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Almehed K, d'Elia HF, Bokarewa M, Carlsten H, Arthritis Res Ther 2008 10 15 10.1186/ar2366 18234104 (Pubitemid 351280042)
149. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I, Mol Cell Biol 1994 14 1431 1437 8289818
150. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H, J Immunol 2007 178 1748 1758 17237424 (Pubitemid 46154646)
151. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC, J Clin Invest 2004 113 1318 1327 15124023 (Pubitemid 39069931)
152. Adipokines as emerging mediators of immune response and inflammation. Lago F, Dieguez C, Gomez-Reino J, Gualillo O, Nat Clin Pract Rheumatol 2007 3 716 724 10.1038/ncprheum0674 18037931 (Pubitemid 350187017)
153. What's new in our understanding of the role of adipokines in rheumatic diseases? Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O, Nat Rev Rheumatol 2011 7 528 536 10.1038/nrrheum.2011.107 21808287